Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885276 | 0.98 | CTSG (0.55) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL612449 | 0.90 | FFAR4 (0.51) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL6112724 | 0.89 | PPARA (0.52) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL7333227 | 0.88 | CA12 (0.54) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL3408740 | 0.88 | KMT2A (0.54) | CTSGCMA1KMT2AFFAR4LMNA | |
| SCHEMBL6112796 | 0.88 | PPARA (0.55) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL8959870 | 0.87 | KMT2A (0.52) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL3407322 | 0.86 | CTSG (0.48) | CTSGCMA1KMT2AFFAR4ALDH1A1 | |
| SCHEMBL4684928 | 0.85 | CA12 (0.55) | CTSGCMA1CA12CA1CA2 | |
| SCHEMBL4684922 | 0.85 | CA12 (0.51) | CTSGCMA1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-11739354-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20220002768-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002769-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3880658-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113227055-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2001062749-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6281243-B1 | ANTIDEPRESSANTS, ANTISEROTONINE AGENT | AKZO NOBEL N.V. (NL) | 2001-08-28 | — | — | US | disclosed |
| WO-1999043647-A1 | DERIVATIVES OF AZETIDINE AND PYRROLIDINE | AKZO NOBEL N.V. (NL) | 1999-09-02 | — | — | WO | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
| US-5066658-A | Enzyme Inhibitors; Bronchodilators; Antiinflammatory Agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-11-19 | — | — | US | disclosed |
| US-4769368-A | DOPAMINE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0233049-A1 | 2,3,4,8,9,9a-Hexahydro-4-aryl-1H-indeno[1,7-cd]azepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4505932-A | AMINOMETHYL-DIHYDROXY (DIALKOXY)-INDOLE, HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CTSG 1602/4885CMA1 860/4885CA12 3011/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | CTSG 645/4885CMA1 2495/4885CA12 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.